Cancer Aware · Patient & Family Guide

Molecular Classification: The Four Major Groups

Molecular classification describes biological features of the tumour. It adds information to stage and histology and can influence both postoperative treatment and treatment of advanced disease.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 9 of 25

Four molecular groups — read alongside stage and histology
  1. POLEmut: qualifying pathogenic proofreading mutation
  2. MMRd: defective DNA mismatch repair
  3. p53abn: abnormal p53 biology after classifier integration
  4. NSMP: none of the other groups; grade and ER refine risk

What you will learn

  • Understand POLE-mutated, MMRd, p53-abnormal and NSMP cancers.
  • Recognize how multiple findings are interpreted.
  • Avoid assuming that one biomarker determines every treatment decision.

POLE-mutated disease

POLE helps copy DNA accurately. Certain pathogenic mutations in its proofreading region create a characteristic tumour group. In cancers confined to the uterus or cervix, this group generally has an excellent prognosis and can support reducing or omitting postoperative treatment in appropriate guideline-defined situations. It does not mean the person has inherited a POLE syndrome.

Not every POLE variant qualifies. A variant of uncertain significance or a nonqualifying change must not be used to label a cancer favourable. Evidence is less secure for advanced POLE-mutated disease; it should not automatically be managed as low risk or downstaged from stage III or IV.

Mismatch repair deficient disease

Mismatch repair proteins correct copying errors in DNA. When this system is deficient, abbreviated MMRd or dMMR, errors accumulate and the cancer may also be microsatellite instability-high, or MSI-H. This biological pattern is important for immunotherapy sensitivity and possible Lynch syndrome evaluation. Many MMRd cancers are caused by acquired changes rather than an inherited mutation.

MMRd does not guarantee an immunotherapy response, and it does not mean every early-stage patient needs immunotherapy. The disease setting, recurrence risk, prior therapy and local approval determine whether treatment is appropriate. A tumour's repair status and a person's inherited genetic status are distinct questions.

p53-abnormal disease

Abnormal p53 staining can indicate a tumour driven by changes in the TP53 pathway. This group often has a higher recurrence risk, particularly with invasion or extrauterine spread. It can strengthen the rationale for combined systemic and local treatment in appropriate high-risk settings. A p53-abnormal tumour result does not automatically imply an inherited TP53 syndrome.

The pathologist interprets the staining pattern, not simply whether some cells are “positive.” Diffuse overexpression, complete absence and other abnormal patterns require appropriate controls and expertise. Unexpected results may need review.

No specific molecular profile

NSMP means the tumour does not fit the other three categories after the required tests. It does not mean no molecular changes exist or that the cancer is harmless. The group is diverse. The 2025 ESGO–ESTRO–ESP guidance further separates low-grade, estrogen-receptor-positive NSMP disease from high-grade or ER-negative NSMP disease for risk assessment.

ER results, grade, LVSI and stage therefore remain important within NSMP. A broad statement that all NSMP cancers have an “intermediate prognosis” hides clinically meaningful differences.

How classification works

Result patternGeneral interpretation
Qualifying pathogenic POLE mutationPOLE group usually takes precedence in multiple-classifier tumours
MMR deficiency without qualifying POLE mutationMMRd generally takes precedence over secondary abnormal p53
Abnormal p53 without the above classifiersp53-abnormal group
None of the above after adequate testingNSMP; grade and ER further refine risk

This is an educational summary, not a tool for self-classification. Some tumours have more than one abnormal test. Expert pathology review prevents a secondary p53 change from incorrectly overriding a POLE or MMRd classification. If POLE testing has not been done, the team should explain the limits of the provisional label and whether testing could change management.

Questions and take-home messages

Ask which tests established your group, whether a variant is pathogenic, and how the result changes your actual options. Molecular classification improves decisions but cannot predict an individual's future with certainty. RAINBO and other studies are testing more tailored treatment; research strategies should not be mistaken for completed evidence.

Related chapters

References and review status

Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy